Glaukos Announces Third Quarter 2024 Financial Results
Glaukos (NYSE: GKOS) reported strong Q3 2024 financial results with record net sales of $96.7 million, up 24% year-over-year. Glaucoma segment achieved record sales of $76.0 million (+30%), while Corneal Health sales reached $20.6 million (+5%). The company maintained a robust gross margin of 77% (82% non-GAAP) and raised its 2024 net sales guidance to $377-379 million. Despite revenue growth, Glaukos reported a net loss of $21.4 million ($0.39 per share), though improved from $30.4 million loss year-over-year. The company ended Q3 with approximately $267.2 million in cash and investments.
Glaukos (NYSE: GKOS) ha riportato risultati finanziari solidi per il terzo trimestre del 2024, con vendite nette record di 96,7 milioni di dollari, in aumento del 24% rispetto all'anno precedente. Il segmento glaucoma ha raggiunto vendite record di 76,0 milioni di dollari (+30%), mentre le vendite nel settore della salute corneale hanno raggiunto 20,6 milioni di dollari (+5%). L'azienda ha mantenuto un robusto margine lordo del 77% (82% non-GAAP) e ha rivisto al rialzo le previsioni di vendite nette per il 2024 a 377-379 milioni di dollari. Nonostante la crescita delle entrate, Glaukos ha riportato una perdita netta di 21,4 milioni di dollari (0,39 dollari per azione), anche se migliorata rispetto alla perdita di 30,4 milioni di dollari dell'anno precedente. L'azienda ha chiuso il terzo trimestre con circa 267,2 milioni di dollari in contante e investimenti.
Glaukos (NYSE: GKOS) informó resultados financieros sólidos para el tercer trimestre de 2024, con ventas netas récord de 96.7 millones de dólares, un aumento del 24% en comparación con el año anterior. El segmento de glaucoma logró ventas récord de 76.0 millones de dólares (+30%), mientras que las ventas de salud corneal alcanzaron los 20.6 millones de dólares (+5%). La compañía mantuvo un sólido margen bruto del 77% (82% no-GAAP) y elevó su guía de ventas netas para 2024 a 377-379 millones de dólares. A pesar del crecimiento en los ingresos, Glaukos reportó una pérdida neta de 21.4 millones de dólares (0.39 dólares por acción), aunque mejoró respecto a la pérdida de 30.4 millones de dólares del año anterior. La compañía cerró el tercer trimestre con aproximadamente 267.2 millones de dólares en efectivo e inversiones.
글라우코스 (NYSE: GKOS)는 2024년 3분기 강력한 재무 결과를 보고했으며, 96.7백만 달러의 기록적인 순매출이 작년 대비 24% 증가했습니다. 녹내장 부문은 76.0백만 달러(+30%)의 기록적인 판매를 달성했으며, 각막 건강 판매는 20.6백만 달러(+5%)에 도달했습니다. 회사는 77%(비-GAAP 기준 82%)의 강력한 매출 총 마진을 유지했으며, 2024년 순매출 가이던스를 3억 7700만 ~ 3억 7900만 달러로 상향 조정했습니다. 매출 성장에도 불구하고, 글라우코스는 2140만 달러(주당 0.39달러)의 순손실을 보고했지만, 이는 지난해 3040만 달러의 손실에 비해 개선된 수치입니다. 회사는 3분기 종료 시 약 2억 6720만 달러의 현금 및 투자를 보유하고 있었습니다.
Glaukos (NYSE: GKOS) a annoncé de solides résultats financiers pour le troisième trimestre 2024, avec des ventes nettes record de 96,7 millions de dollars, en hausse de 24 % par rapport à l'année précédente. Le segment glaucome a réalisé des ventes record de 76,0 millions de dollars (+30 %), tandis que les ventes dans le domaine de la santé cornéenne ont atteint 20,6 millions de dollars (+5 %). L'entreprise a maintenu une solide marge brute de 77 % (82 % non-GAAP) et a relevé ses prévisions de ventes nettes pour 2024 à 377-379 millions de dollars. Malgré la croissance des revenus, Glaukos a enregistré une perte nette de 21,4 millions de dollars (0,39 dollar par action), bien que celle-ci soit une amélioration par rapport à une perte de 30,4 millions de dollars l'année précédente. L'entreprise a terminé le troisième trimestre avec environ 267,2 millions de dollars en espèces et investissements.
Glaukos (NYSE: GKOS) berichtete über starke Finanzergebnisse im dritten Quartal 2024 mit Rekordnettoverkäufen von 96,7 Millionen Dollar, was einem Anstieg von 24% im Vergleich zum Vorjahr entspricht. Der Glaukom-Sektor erzielte Rekordverkäufe von 76,0 Millionen Dollar (+30%), während die Verkäufe im Bereich Hornhautgesundheit 20,6 Millionen Dollar (+5%) erreichten. Das Unternehmen hielt eine robuste Bruttomarge von 77% (82% non-GAAP) aufrecht und erhöhte seine Prognose für die Nettoverkäufe 2024 auf 377-379 Millionen Dollar. Trotz des Umsatzwachstums meldete Glaukos einen Nettoverlust von 21,4 Millionen Dollar (0,39 Dollar pro Aktie), was jedoch eine Verbesserung gegenüber dem Verlust von 30,4 Millionen Dollar im Vorjahr darstellt. Das Unternehmen schloss das dritte Quartal mit etwa 267,2 Millionen Dollar in Bargeld und Investitionen ab.
- Record net sales of $96.7M, up 24% YoY
- Glaucoma segment sales increased 30% to $76.0M
- Improved net loss from $30.4M to $21.4M YoY
- Raised full-year revenue guidance to $377-379M
- Strong gross margin of 77% (82% non-GAAP)
- Healthy cash position of $267.2M
- Operating loss of $24.7M in Q3
- Net loss of $21.4M ($0.39 per share)
- SG&A expenses increased 18% to $64.0M
- R&D expenses increased 4% to $34.7M
Insights
The Q3 results showcase significant momentum with
Despite robust top-line growth, operating losses continue, though narrowing to
-
Record net sales of
$96.7 million 24% year-over-year. -
Glaucoma record net sales of
$76.0 million 30% year-over-year. -
Corneal Health net sales of
$20.6 million 5% year-over-year. -
Gross margin of approximately
77% and non-GAAP gross margin of approximately82% . -
Raised 2024 net sales guidance to
$377 million $379 million $370 million $376 million
“Our record third quarter results reflect successful global execution of our key strategic plans and continued strong momentum in our business,” said Thomas Burns, Glaukos chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”
Third Quarter 2024 Financial Results
Net sales in the third quarter of 2024 of
Gross margin for the third quarter of 2024 was approximately
Selling, general and administrative (SG&A) expenses for the third quarter of 2024 increased
GAAP and non-GAAP research and development (R&D) expenses for the third quarter of 2024 increased
Loss from operations in the third quarter of 2024 was
Net loss in the third quarter of 2024 was
The company ended the third quarter of 2024 with approximately
2024 Revenue Guidance
The company expects 2024 net sales to be in the range of
Webcast & Conference Call
The company will host a conference call and simultaneous webcast today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and provide additional information about the company’s financial outlook. A link to the webcast is available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (
Quarterly Summary Document
The company has posted a document on its Investor Relations website under the “Financials & Filings – Quarterly Results” section titled “Quarterly Summary.” This Quarterly Summary document is designed to provide the investment community with a summarized and easily accessible reference document that details the key facts associated with the quarter, the state of the company’s business objectives and strategies and any forward statements or guidance the company may make. This document is provided alongside the company’s earnings press release and is designed to be read by investors before the regularly scheduled quarterly conference call. As such, today’s conference call will be in a format primarily consisting of a questions and answers session, during which Glaukos will address any queries investors have regarding the company’s results. It is the company’s goal that this format will make its quarterly earnings process more efficient and impactful for the investment community going forward.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of federal securities laws. All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, our ability to successfully commercialize our iDose TR therapy; the impact of general macroeconomic conditions including foreign currency fluctuations and future health crises on our business; our ability to continue to generate sales of our commercialized products and develop and commercialize additional products; our dependence on a limited number of third-party suppliers, some of which are single-source, for components of our products; the occurrence of a crippling accident, natural disaster, or other disruption at our primary facility, which may materially affect our manufacturing capacity and operations; securing or maintaining adequate coverage or reimbursement by third-party payors for procedures using the iStent, the iStent inject W, iAccess, iPRIME, iStent infinite, iDose TR, our corneal cross-linking products or other products in development, and our compliance with the requirements of participation in federal healthcare programs such as Medicare and Medicaid; our compliance with federal, state and foreign laws and regulations for the approval and sale and marketing of our products and of our manufacturing processes; the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; the risk of recalls or serious safety issues with our products and the uncertainty of patient outcomes; our ability to protect our information systems against cyber threats and cybersecurity incidents, and to comply with state, federal and foreign data privacy laws and regulations; our ability to protect, and the expense and time-consuming nature of protecting our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation; and our ability to service our indebtedness. These and other known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (SEC), including in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, which was filed with the SEC on August 2, 2024, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which is expected to be filed with the SEC by November 12, 2024. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
Statement Regarding Use of Non-GAAP Financial Measures
To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles (“GAAP”), the Company uses certain non-GAAP historical financial measures. Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company’s industry to enhance comparability of the Company's financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations) (“Non-GAAP Purposes”). The Company uses the term “Non-GAAP” to exclude certain expenses, gains and losses to achieve the Non-GAAP Purposes, including external acquisition-related costs incurred to effect a business combination; amortization of intangible assets acquired in a business combination, asset purchase transaction or other contractual relationship; impairment of goodwill and intangible assets; certain in-process R&D charges; fair value adjustments to contingent consideration liabilities and pre-acquisition contingencies arising from a business combination; integration and transition costs related to business combinations; fair market value adjustments to inventories acquired in a business combination or asset purchase transaction; restructuring charges, duplicative operating expenses, or asset write-offs (or reversals) associated with exiting or significantly downsizing a business; gain or loss from the sale of a business; gain or loss on the mark-to-market adjustment, impairment, or sale of long-term investments; mark-to-market adjustments on derivative instruments that hedge income or expense exposures in a future period; significant legal litigation costs and/or settlement expenses or proceeds; legal and other associated expenses that are both unusual and significant related to governmental or internal inquiries; expenses, acceleration of amortization of debt issuance costs and gain or loss on debt extinguishment associated with the exchange or redemption of convertible senior notes; and significant discrete income and other tax adjustments related to transactions as well as changes in estimated acquisition-date tax effects associated with business combinations, and the impact from implementation of tax law changes and settlements. See “GAAP to Non-GAAP Reconciliations” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure.
In addition, in order to remove the impact of fluctuations in foreign currency exchange rates, the Company also presents certain net sales information on a constant currency basis, which represents the outcome that would have resulted had exchange rates in the current period been the same as the average exchange rates in effect in the comparable prior period. See “Reported Sales vs. Prior Periods” for a presentation of certain net sales information on a reported, GAAP and a constant currency basis.
| GLAUKOS CORPORATION | ||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| (in thousands, except per share amounts) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
2024 |
2023 |
2024 |
2023 |
|||||||||||||
| Net sales | $ |
96,670 |
|
$ |
78,048 |
|
$ |
277,982 |
|
$ |
232,346 |
|
||||
| Cost of sales |
|
22,584 |
|
|
18,510 |
|
|
65,392 |
|
|
56,684 |
|
||||
| Gross profit |
|
74,086 |
|
|
59,538 |
|
|
212,590 |
|
|
175,662 |
|
||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative |
|
64,000 |
|
|
54,247 |
|
|
192,163 |
|
|
161,034 |
|
||||
| Research and development |
|
34,746 |
|
|
33,301 |
|
|
99,898 |
|
|
101,706 |
|
||||
| Acquired in-process research and development |
|
- |
|
|
- |
|
|
14,229 |
|
|
3,000 |
|
||||
| Total operating expenses |
|
98,746 |
|
|
87,548 |
|
|
306,290 |
|
|
265,740 |
|
||||
| Loss from operations |
|
(24,660 |
) |
|
(28,010 |
) |
|
(93,700 |
) |
|
(90,078 |
) |
||||
| Non-operating income (expense): | ||||||||||||||||
| Interest income |
|
2,700 |
|
|
2,710 |
|
|
8,611 |
|
|
6,252 |
|
||||
| Interest expense |
|
(1,663 |
) |
|
(3,398 |
) |
|
(8,468 |
) |
|
(10,205 |
) |
||||
| Charges associated with convertible senior notes |
|
- |
|
|
- |
|
|
(18,012 |
) |
|
- |
|
||||
| Other income (expense), net |
|
2,391 |
|
|
(1,709 |
) |
|
(338 |
) |
|
(2,978 |
) |
||||
| Total non-operating income (expense) |
|
3,428 |
|
|
(2,397 |
) |
|
(18,207 |
) |
|
(6,931 |
) |
||||
| Loss before taxes |
|
(21,232 |
) |
|
(30,407 |
) |
|
(111,907 |
) |
|
(97,009 |
) |
||||
| Income tax provision |
|
177 |
|
|
37 |
|
|
885 |
|
|
873 |
|
||||
| Net loss | $ |
(21,409 |
) |
$ |
(30,444 |
) |
$ |
(112,792 |
) |
$ |
(97,882 |
) |
||||
| Basic and diluted net loss per share | $ |
(0.39 |
) |
$ |
(0.63 |
) |
$ |
(2.18 |
) |
$ |
(2.03 |
) |
||||
| Weighted average shares used to compute basic and diluted net loss per share |
|
55,037 |
|
|
48,675 |
|
|
51,804 |
|
|
48,284 |
|
||||
| GLAUKOS CORPORATION | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| (in thousands, except par values) | ||||||||
September 30, |
December 31, |
|||||||
2024 |
2023 |
|||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ |
100,143 |
|
$ |
93,467 |
|
||
| Short-term investments |
|
162,330 |
|
|
201,964 |
|
||
| Accounts receivable, net |
|
56,408 |
|
|
39,850 |
|
||
| Inventory |
|
59,895 |
|
|
41,986 |
|
||
| Prepaid expenses and other current assets |
|
18,506 |
|
|
18,194 |
|
||
| Total current assets |
|
397,282 |
|
|
395,461 |
|
||
| Restricted cash |
|
4,733 |
|
|
5,856 |
|
||
| Property and equipment, net |
|
98,581 |
|
|
103,212 |
|
||
| Operating lease right-of-use assets |
|
27,321 |
|
|
27,146 |
|
||
| Finance lease right-of-use asset |
|
42,365 |
|
|
44,180 |
|
||
| Intangible assets, net |
|
269,418 |
|
|
282,956 |
|
||
| Goodwill |
|
66,134 |
|
|
66,134 |
|
||
| Deposits and other assets |
|
20,709 |
|
|
15,469 |
|
||
| Total assets | $ |
926,543 |
|
$ |
940,414 |
|
||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ |
11,103 |
|
$ |
13,440 |
|
||
| Accrued liabilities |
|
60,581 |
|
|
60,574 |
|
||
| Total current liabilities |
|
71,684 |
|
|
74,014 |
|
||
| Convertible senior notes |
|
56,759 |
|
|
282,773 |
|
||
| Operating lease liability |
|
30,656 |
|
|
30,427 |
|
||
| Finance lease liability |
|
69,712 |
|
|
70,538 |
|
||
| Deferred tax liability, net |
|
7,143 |
|
|
7,144 |
|
||
| Other liabilities |
|
22,080 |
|
|
13,752 |
|
||
| Total liabilities |
|
258,034 |
|
|
478,648 |
|
||
| Stockholders' equity: | ||||||||
| Preferred stock, |
|
- |
|
|
- |
|
||
| Common stock, |
|
55 |
|
|
49 |
|
||
| Additional paid-in capital |
|
1,377,825 |
|
|
1,059,751 |
|
||
| Accumulated other comprehensive income |
|
2,620 |
|
|
1,165 |
|
||
| Accumulated deficit |
|
(711,859 |
) |
|
(599,067 |
) |
||
| Less treasury stock (28 shares as of September 30, 2024 and December 31, 2023) |
|
(132 |
) |
|
(132 |
) |
||
| Total stockholders' equity |
|
668,509 |
|
|
461,766 |
|
||
| Total liabilities and stockholders' equity | $ |
926,543 |
|
$ |
940,414 |
|
||
| GLAUKOS CORPORATION | ||||||||||||||||||||||||||
| GAAP to Non-GAAP Reconciliations | ||||||||||||||||||||||||||
| (in thousands, except per share amounts and percentage data) | ||||||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||||
| Q3 2024 | Q3 2023 | |||||||||||||||||||||||||
| GAAP | Adjustments | Non-GAAP | GAAP | Adjustments | Non-GAAP | |||||||||||||||||||||
| Cost of sales | $ |
22,584 |
$ |
(5,523 |
) |
(a) | $ |
17,061 |
|
$ |
18,510 |
|
$ |
(5,523 |
) |
(a) | $ |
12,987 |
|
|||||||
| Gross Margin |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||||
| Selling, general and administrative | $ |
64,000 |
|
$ |
(705 |
) |
(b) | $ |
63,295 |
|
$ |
54,247 |
|
$ |
(705 |
) |
(b) | $ |
53,542 |
|
||||||
| Loss from operations | $ |
(24,660 |
) |
$ |
6,228 |
|
$ |
(18,432 |
) |
$ |
(28,010 |
) |
$ |
6,228 |
|
$ |
(21,782 |
) |
||||||||
| Net loss | $ |
(21,409 |
) |
$ |
6,228 |
|
(c) | $ |
(15,181 |
) |
$ |
(30,444 |
) |
$ |
6,228 |
|
(c) | $ |
(24,216 |
) |
||||||
| Basic and diluted net loss per share | $ |
(0.39 |
) |
$ |
0.11 |
|
$ |
(0.28 |
) |
$ |
(0.63 |
) |
$ |
0.13 |
|
$ |
(0.50 |
) |
||||||||
(a) |
Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of |
||||||||||
(b) |
Avedro acquisition-related amortization expense of customer relationship intangible assets of |
||||||||||
(c) |
Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the |
||||||||||
| GLAUKOS CORPORATION | ||||||||||||||||||||||||||
| GAAP to Non-GAAP Reconciliations | ||||||||||||||||||||||||||
| (in thousands, except per share amounts and percentage data) | ||||||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||||
| Year-to-Date Q3 2024 | Year-to-Date Q3 2023 | |||||||||||||||||||||||||
| GAAP | Adjustments | Non-GAAP | GAAP | Adjustments | Non-GAAP | |||||||||||||||||||||
| Cost of sales | $ |
65,392 |
|
$ |
(16,569 |
) |
(a) | $ |
48,823 |
|
$ |
56,684 |
|
$ |
(16,569 |
) |
(a) | $ |
40,115 |
|
||||||
| Gross Margin |
|
|
|
|
|
|
|
75.6 |
% |
|
|
|
|
|||||||||||||
| Operating expenses: | ||||||||||||||||||||||||||
| Selling, general and administrative | $ |
192,163 |
|
$ |
(2,115 |
) |
(b) | $ |
190,048 |
|
$ |
161,034 |
|
$ |
(2,115 |
) |
(b) | $ |
158,919 |
|
||||||
| Loss from operations | $ |
(93,700 |
) |
$ |
18,684 |
|
$ |
(75,016 |
) |
$ |
(90,078 |
) |
$ |
18,684 |
|
$ |
(71,394 |
) |
||||||||
| Non-operating income (expense): | ||||||||||||||||||||||||||
| Charges associated with convertible senior notes | $ |
(18,012 |
) |
$ |
18,012 |
|
(c) | $ |
- |
|
$ |
- |
|
$ |
- |
|
$ |
- |
|
|||||||
| Net loss | $ |
(112,792 |
) |
$ |
36,696 |
|
(d) | $ |
(76,096 |
) |
$ |
(97,882 |
) |
$ |
18,684 |
|
(d) | $ |
(79,198 |
) |
||||||
| Basic and diluted net loss per share | $ |
(2.18 |
) |
$ |
0.71 |
|
$ |
(1.47 |
) |
$ |
(2.03 |
) |
$ |
0.39 |
|
$ |
(1.64 |
) |
||||||||
(a) |
Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of |
||||||||||
(b) |
Avedro acquisition-related amortization expense of customer relationship intangible assets of |
||||||||||
(c) |
Expenses associated with the exchange of convertible senior notes, consisting of a non-cash inducement charge of |
||||||||||
(d) |
Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the |
||||||||||
|
|||||||||||||
| Reported Sales vs. Prior Periods (in thousands) | |||||||||||||
| Year-over-Year Percent Change | Quarter-over-Quarter Percent Change | ||||||||||||
3Q 2024 |
3Q 2023 |
2Q 2024 |
Reported |
Operations (1) |
Currency (2) |
Reported |
Operations (1) |
Currency (2) |
|||||
| International Glaucoma | $ |
24,467 |
$ |
20,280 |
$ |
26,131 |
|
|
( |
( |
( |
|
|
| Total Net Sales | $ |
96,670 |
$ |
78,048 |
$ |
95,690 |
|
|
( |
|
|
|
|
| (1) Operational growth excludes the effect of translational currency | |||||||||||||
| (2) Calculated by converting the current period numbers using the prior period’s average foreign exchange rates | |||||||||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104442542/en/
Chris Lewis
Vice President, Investor Relations & Corporate Affairs
(949) 481-0510
clewis@glaukos.com
Source: Glaukos Corporation
FAQ
What was Glaukos (GKOS) Q3 2024 revenue?
What is Glaukos (GKOS) revenue guidance for 2024?
What was Glaukos (GKOS) Q3 2024 earnings per share?
How much cash does Glaukos (GKOS) have as of Q3 2024?
